Overview

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib and Tislelizumab in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

Status:
Not yet recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of tislelizumab in combination with sitavatinib in advanced triple-negative breast cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University